164 related articles for article (PubMed ID: 33590502)
1. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Benevolo G; Elli EM; Bartoletti D; Latagliata R; Tiribelli M; Heidel FH; Cavazzini F; Bonifacio M; Crugnola M; Binotto G; D'Addio A; Tieghi A; Bergamaschi M; Caocci G; Polverelli N; Bossi E; Auteri G; Carmosino I; Catani L; Cuneo A; Krampera M; Lanza F; Lemoli RM; Vianelli N; Breccia M; Palumbo GA; Cavo M; Palandri F
Hematol Oncol; 2021 Aug; 39(3):409-418. PubMed ID: 33590502
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors.
Teng G; Zhou Y; Zhang Y; Hu N; Liu T; Han Y; Gao C; Zhang L; Bai J
Thromb Res; 2022 Apr; 212():38-43. PubMed ID: 35219930
[TBL] [Abstract][Full Text] [Related]
3. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F; Rumi E; Caramella M; Elena C; Arcaini L; Boveri E; Del Curto C; Pietra D; Vanelli L; Bernasconi P; Pascutto C; Cazzola M; Morra E; Lazzarino M
Blood; 2008 Apr; 111(7):3383-7. PubMed ID: 18187660
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
5. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
6. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Tam CS; Kantarjian H; Cortes J; Lynn A; Pierce S; Zhou L; Keating MJ; Thomas DA; Verstovsek S
J Clin Oncol; 2009 Nov; 27(33):5587-93. PubMed ID: 19786661
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
8. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Breccia M; Bartoletti D; Bonifacio M; Palumbo GA; Polverelli N; Abruzzese E; Bergamaschi M; Tieghi A; Tiribelli M; Iurlo A; Cavazzini F; Sgherza N; Binotto G; Isidori A; D'Adda M; Crugnola M; Bosi C; Heidel F; Molica M; Scaffidi L; Cattaneo D; Latagliata R; Auteri G; Lemoli RM; Fanin R; Russo D; Aversa F; Cuneo A; Semenzato G; Catani L; Cavo M; Vianelli N; Foà R; Palandri F
Ann Hematol; 2019 Apr; 98(4):889-896. PubMed ID: 30515542
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
Ann Intern Med; 1995 Nov; 123(9):656-64. PubMed ID: 7574220
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Mancuso S; Santoro M; Accurso V; Agliastro G; Raso S; Di Piazza F; Perez A; Bono M; Russo A; Siragusa S
Oncol Res Treat; 2020; 43(10):526-530. PubMed ID: 32772025
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
Kerbauy DM; Gooley TA; Sale GE; Flowers ME; Doney KC; Georges GE; Greene JE; Linenberger M; Petersdorf E; Sandmaier BM; Scott BL; Sorror M; Stirewalt DL; Stewart FM; Witherspoon RP; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
[TBL] [Abstract][Full Text] [Related]
14. [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center].
Bai J; Shi H; Ai L; Zhang L; Zhou Y; Li Z; Zhao Y; Sheng M; Li D; Li H; Qian L; Mi Y; Xiao Z; Zheng Y; Yang R; Xue Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1364-8. PubMed ID: 26178350
[TBL] [Abstract][Full Text] [Related]
15. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
16. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
17. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
18. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
[TBL] [Abstract][Full Text] [Related]
19. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
